Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) - Total Liabilities
Based on the latest financial reports, Hubei Biocause Heilen Pharmaceutical Co. Ltd. (301211) has total liabilities worth CN¥117.63 Million CNY (≈ $17.21 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Hubei Biocause Heilen Pharmaceutical Co. to evaluate the company's liquid asset resilience ratio.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. - Total Liabilities Trend (2017–2025)
This chart illustrates how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Hubei Biocause Heilen Pharmaceutical Co. assets under control.
Hubei Biocause Heilen Pharmaceutical Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Hubei Biocause Heilen Pharmaceutical Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Southern Cable Group Bhd
KLSE:0225
|
Malaysia | RM419.67 Million |
|
Ulker Biskuvi Sanayi AS
IS:ULKER
|
Turkey | TL86.63 Billion |
|
Shenzhen Urovo Technology Co Ltd
SHE:300531
|
China | CN¥1.08 Billion |
|
First Hi-tec Enterprise Co Ltd
TWO:5439
|
Taiwan | NT$6.87 Billion |
|
BAE Systems plc
LSE:BA
|
UK | GBX25.74 Billion |
|
Bajaj Consumer Care Limited
NSE:BAJAJCON
|
India | Rs1.90 Billion |
|
ZENTIVA S.A.
RO:SCD
|
Romania | RON350.60 Million |
|
N-Able Inc
NYSE:NABL
|
USA | $596.49 Million |
Liability Composition Analysis (2017–2025)
This chart breaks down Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Hubei Biocause Heilen Pharmaceutical Co. net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 17.18 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.05 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Hubei Biocause Heilen Pharmaceutical Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Hubei Biocause Heilen Pharmaceutical Co. Ltd. (2017–2025)
The table below shows the annual total liabilities of Hubei Biocause Heilen Pharmaceutical Co. Ltd. from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥128.65 Million ≈ $18.83 Million |
-28.12% |
| 2024-12-31 | CN¥178.97 Million ≈ $26.19 Million |
-5.75% |
| 2023-12-31 | CN¥189.89 Million ≈ $27.79 Million |
-14.16% |
| 2022-12-31 | CN¥221.22 Million ≈ $32.37 Million |
+105.73% |
| 2021-12-31 | CN¥107.53 Million ≈ $15.73 Million |
+4.55% |
| 2020-12-31 | CN¥102.85 Million ≈ $15.05 Million |
-60.03% |
| 2019-12-31 | CN¥257.31 Million ≈ $37.65 Million |
+7.05% |
| 2018-12-31 | CN¥240.36 Million ≈ $35.17 Million |
+5.77% |
| 2017-12-31 | CN¥227.25 Million ≈ $33.25 Million |
-- |
About Hubei Biocause Heilen Pharmaceutical Co. Ltd.
Hubei Biocause Heilen Pharmaceutical Co., Ltd. engages in the pharmaceutical, chemical, and new energy fuel businesses in China and internationally. It is involved in the research and development, production, and sales of chemical raw materials and preparations; and provision of contract research and development, and production services. The company also provides raw material products, including … Read more